These results highlight potential regulatory mechanisms and therapeutic strategies involving CD109 and CPA3 in AR and CRSwNP, suggesting new avenues for targeted therapies and their associated regulatory networks. The gene discussed is CD109; the disease is chronic rhinosinusitis with nasal polyps.